OSTEOLITE Drug Patent Profile
✉ Email this page to a colleague
When do Osteolite patents expire, and when can generic versions of Osteolite launch?
Osteolite is a drug marketed by Pharmalucence and is included in one NDA.
The generic ingredient in OSTEOLITE is technetium tc-99m medronate kit. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the technetium tc-99m medronate kit profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Osteolite
A generic version of OSTEOLITE was approved as technetium tc-99m medronate kit by CARDINAL HEALTH 414 on December 31st, 1969.
Summary for OSTEOLITE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OSTEOLITE at DailyMed |
US Patents and Regulatory Information for OSTEOLITE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmalucence | OSTEOLITE | technetium tc-99m medronate kit | INJECTABLE;INJECTION | 017972-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |